XML 27 R17.htm IDEA: XBRL DOCUMENT

Legal Settlements and Loss Contingencies	3 Months Ended
Mar. 31, 2021
Legal Settlements and Loss Contingencies	NOTE 9 – Legal settlements and loss contingencies: Legal settlements and loss contingencies for the first quarter of 2021 were $104 million, compared to an income of $25 million in the first quarter of 2020. The expense in the first quarter of 2021 was mainly due to the provision for the carvedilol patent litigation (see note 10). The income in the first quarter of 2020 was mainly due to proceeds received following a settlement of an action brought against the sellers of Auden McKenzie (an acquisition made by Actavis Generics). As of March 31, 2021 and December 31, 2020, Teva’s provision for legal settlements and loss contingencies recorded under accrued expenses and other taxes and long-term liabilities was $1,730 million and 1,625 million, respectively.

Legal Settlements and Loss Contingencies

3 Months Ended

Mar. 31, 2021

Legal Settlements and Loss Contingencies

NOTE 9 – Legal settlements and loss contingencies:

Legal settlements and loss contingencies for the first quarter of 2021

were

$104 million, compared to an income of $25 million in the first quarter of 2020. The expense in the first quarter of 2021 was mainly due to the provision for the carvedilol patent litigation (see note 10). The income in the first quarter of 2020 was mainly due to proceeds received following a settlement of an action brought against the sellers of Auden McKenzie (an acquisition made by Actavis Generics).

As of March 31, 2021 and December 31, 2020, Teva’s provision for legal settlements and loss contingencies recorded under accrued expenses and other taxes and long-term liabilities was $1,730 million and 1,625 million, respectively.